retatrutide clinical studies Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide Results: 28.3% Weight Loss

This is where the phase 3-stage fatty liver disease drug pegozafermin, acquired as part of the buyout of 89bio last week, comes into play

SCIENTIFIC REFERENCES Lodi, R., et al

Cancer 109 (10), 19491956

faecalis promotes the formation of fungal filaments and the release of Candidalysin, while the fungus enhances the activity of E

NICE recommend tirzepatide and semaglutide for patients with at least one weight-related comorbidity and a BMI 35 kg/m 2 (or BMI 30 kg/m 2 and who meet the criteria for referral to specialist weight management services, for semaglutide only) and liraglutide for patients with a BMI 35 kg/m 2 , non-diabetic hyperglycaemia, and a high risk of cardiovascular disease